Ignite Creation Date:
2024-05-05 @ 11:46 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00120328
Status:
TERMINATED
Last Update Posted:
2007-10-05
First Post:
2005-06-30
Brief Title:
To Determine the Effects of Avosentan on Doubling of Serum Creatinine End Stage Renal Disease and Death in Diabetic Nephropathy
Sponsor:
Speedel Pharma Ltd
Organization:
Speedel Pharma Ltd
Key Dates - Follows AllAPIJSON File Order
Start Date:
2005-07
Start Date Type:
None
Primary Completion Date:
None
Primary Completion Date Type:
None
Completion Date:
2007-02
Completion Date Type:
ACTUAL
First Submit Date:
2005-06-30
First Submit QC Date:
July 7 2005
Study First Post Date:
2005-07-15
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2007-10-04
Last Update Post Date:
2007-10-05
Last Update Post Date Type:
ESTIMATED